Acute Pain News and Research

RSS

Trevena prices initial public offering of common stock

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share.

31 Jan 2014

ASA's recommendations to help patients avoid unnecessary tests for chronic pain

Not prescribing opioids first or as a long-term therapy for chronic, non-cancer pain and avoiding MRIs, CTs and X-rays for low-back pain are among the tests and treatments identified by ASA that are commonly ordered but not always necessary.

22 Jan 2014

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.

15 Jan 2014

Researchers study changes in gray matter volume in chronic back pain patients

Accumulating evidence indicates that chronic pain of different etiologies is often associated with distinct gray matter volume reductions in multiple brain regions associated with acute pain processing, and gray matter atrophy critically affects the perception and modulation of chronic pain.

6 Jan 2014

MEDNAX acquires Summit Anesthesia Associates

MEDNAX, Inc., today announced the acquisition of Summit Anesthesia Associates, P.A., a physician group practice primarily based in Summit, New Jersey. The practice will become part of MEDNAX's American Anesthesiology division and is the second New Jersey-based anesthesiology practice to join this division.

2 Jan 2014

Researchers find evidence that gout clusters in families

It's historically known as 'the king of diseases and the disease of kings' and was long thought to be caused by an overindulgent lifestyle, but now scientists at The University of Nottingham have confirmed that 'gout' strongly runs in families.

3 Dec 2013

QRxPharma refiles MOXDUO New Drug Application with US FDA

QRxPharma Limited announced today that the Company resubmitted its MOXDUO New Drug Application. At a meeting in early October, the United States Food and Drug Administration provided QRxPharma with guidance on its requirements for the NDA refiling as well as data validation documentation.

26 Nov 2013

Absence of vision from birth leads to permanent state of pain hypersensitivity, shows report

Absence of vision from birth leads to a permanent state of pain hypersensitivity, reports PAIN. An international team of scientists investigated whether congenitally blind subjects experience pain differently than sighted individuals. Their results, published in the current issue of PAIN®, reveal compelling evidence that congenitally blind individuals are hypersensitive to pain caused by thermal stimuli.

3 Nov 2013

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

$Vertebral augmentation for spinal fractures improves patient survival, reduces overall costs$

Vertebral augmentation for spinal fractures improves patient survival, reduces overall costs

A study of 69,000 Medicare patient records led by Johns Hopkins researchers shows that people with spine compression fractures who undergo operations to strengthen back bones with cement survive longer and have shorter overall hospital stays than those who stick with bed rest, pain control and physical therapy.

18 Oct 2013

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE, a pharmaceutical company focused on developing novel therapeutics for pain today announces positive top line results from its recently completed phase II trial, which was designed to evaluate the efficacy and safety of E-58425 in acute pain.

16 Oct 2013

Polyamine-deficient diets effective as pain relief treatment for chronic and acute pain

Before and after spinal surgery, patients on a polyamine-deficient diets experienced significant relief of both chronic and acute pain, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

14 Oct 2013

Team Ritter to raise funds for John Ritter Foundation for Aortic Health at ING NYC Marathon

Friends and family members of people with thoracic aortic disease and fans of the late legendary comedic actor John Ritter will come together as Team Ritter to raise funds for the John Ritter Foundation for Aortic Health at the ING New York City Marathon on Nov. 3, 2013.

10 Oct 2013

MNK-795 for acute pain management: an interview with Dr Lynn Webster

MNK-795 is a product in development that is intended to be used for acute pain. It has some unique properties. First, it is an extended release formulation, meaning that it’s going to last more than three to four hours. It was studied to be dosed once every 12 hours, and that is unique for an acute pain formulation.

8 Oct 2013

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Food and Drug Administration for Zalviso (sufentanil sublingual microtablet system).

30 Sep 2013

Arginine therapy may be safe treatment for patients with sickle cell disease

Arginine therapy may be a safe and inexpensive treatment for acute pain episodes in patients with sickle cell disease, according to results of a recent clinical study. The study was the first randomized placebo-controlled study to demonstrate benefits of arginine therapy in children with sickle cell disease hospitalized for severe pain.

17 Sep 2013

NIH budget slashing may stall future pain research funding

Multi-faceted pain research discoveries within the last decade are bringing new hope for the estimated 100 million Americans with chronic pain. Unfortunately, translation of these scientific advances into clinical practice could be stalled without sufficient funding for both basic science and clinical pain research, according to the American Pain Society.

12 Sep 2013

FDA schedules meeting on 3 October to discuss QRxPharma's MOXDUO NDA for acute pain

QRxPharma Limited announced today the United States Food and Drug Administration has scheduled a meeting on 3 October to discuss the Company's MOXDUO New Drug Application for the treatment of moderate to severe acute pain.

6 Sep 2013

Drug for children with sickle cell anemia reduces hospitalizations and treatment costs

A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children's Research Hospital. The report appears today in the advance online edition of the journal Pediatrics.

2 Sep 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013